Navigation Links
Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer


Measure mutations in any tissue with the Big Blue transgenic rodent mutation assay

Johan G. de Boer Barry W. Glickman
Centre for Environmental Health, University of Victoria, Victoria, BC Canada

With Stratagenes Big Blue transgenic rodent mutation assay,* which carries the E. coli lacI transgene in a retrievable chromosomally integrated shuttle vector, it is easy to study mutations in male and female mice or rats of any age under selected conditions in vivo. Multilab studies indicate that mutations are generally induced in the same tissue that tumors are produced but not in nontarget tissues. This makes the transgenic model for the study of genotoxicity even more valuable, since mutations can be studied in virtually any tissue.

The hallmark of occupational- and lifestyle-related cancer is tissue specificity. Human exposures to carcinogens result in particular types of cancer at predictable sites; tobacco smoke, arsenic, and ionizing radiation all produce their own unique kinds of cancers in preferred tissues. Tissue specificity is also a feature of animal model systems. For example, when male mice are exposed to the flame retardant tris(2,3-dibromopropyl)phosphate (TDBP), they contract kidney tumors, and the alkylating agent dimethylnitrosamine predominantly produces liver, kidney, and lung tumors. Sex can also have an impact on tissue targeting. In the case of TDBP, liver tumors predominate in female mice, while kidney tumors are seen in male mice.

Figure 1

This kind of information is crucial for identifying suspected carcinogens. Hence, we ask a critical question: Does mutation follow the same pattern as the targeting of tumors? In other words, are mutations being induced in tissues where tumors are recovered and not in others? Big Blue transgenic rodents with recoverable mutation target genes make use of the well-characterized bacterial lacI gene as a mutational target gene. The lacI gene, part of the lLIZ shuttle vector, is present in approximately 40 copies per chromosome in the mouse and rat. Mutations are efficiently assessed through the recovery of the l genome (Figure 1). High molecular weight genomic DNA is isolated from any selected Big Blue transgenic rodent tissue, which can be facilitated with the RecoverEase DNA isolation kit, and the l genomes are packaged into phage particles by Transpack lambda packaging extract.** The l particles are then plated on a specially constructed E. coli host in the presence of the chromogenic compound X-gal. Phages carrying the mutated lacI gene produce blue plaques, whereas the wild-type gene yields colorless plaques.

The ratio of blue to clear plaques indicates the mutant frequency, which in most tissues varies between 2 to 6 x 10-5, although it is often lower in the rat than the mouse. Subsequent sequencing of the mutant lacI genes reveals the specific nature of the DNA change at the molecular level; when a sufficient number of mutants have been sequenced, a mutational spectrum results. Mutational spectra are extremely useful in assessing the mechanism of mutation. DNA sequencing also permits the mutant frequency to be adjusted by allowing a correction for clonal expansion in which an individual mutation is recovered multiple times because of cell division.

Tissue Specific Effects

Researchers who have designed studies to assess mutations in a range of tissues after carcinogen treatment have addressed whether mutations are induced selectively in those tissues targeted for tumorigenesis. We reviewed some of the available data to illustrate how the Big Blue transgenic rodent mutagenesis assay system is used in tissue-specific studies (Table 1).

Table 1
Induction of Tumors and Mutations in Target and Nontarget Tissues by Selected Carcingens

Compound

Tumor target

Mutations

No mutations

DMN2,3

Liver, kidney, lung

Liver, kidney, lung

Bladder, bone marrow, testis

TDBP1

Kidney

Kidney, liver

Stomach

PhIP*

Colon

Colon

Liver

MeIQ10

Colon, liver, skin, mammary gland

Colon, liver, skin, mammary gland

Heart

Ethylene oxide7

lung

lung

Spleen, bone marrow, germ cells

Benzene8

Lung, leukemia, lymphomas

Lung, spleen

liver

* De Boer et al., unpublished
See text for additional details.

TDBP

The flame retardant tris(2,3-dibromopropyl)phosphate (TDBP) is an established kidney-specific carcinogen in male and female rats and male mice; in female mice, it targets the liver. In a TDBP study,1 the lacI mutation frequency was determined in the kidney, liver, and stomach of male Big Blue mice after treatment with 2000 ppm of TDBP. The mutant frequency increased marginally in the kidney and liver (approximately 50%) but not the stomach. Sequencing the mutants revealed a unique difference in mutational spectrum: The spectrum from the liver was indistinguishable from that of untreated animals, while that from the kidney included unique deletions of single GC base pairs. Thus, in this case, TDBP-specific mutations were induced only in the tissue where tumors were recovered. Hence, DNA sequencing can improve the assay sensitivity in situations where the induced mutant frequency is low.

DMN

Tissue specificity was also observed with dimethylnitrosamine (DMN), which has been well studied in the liver.2 DMN produces tumors in various organs including the liver, kidney, and lung. Suzuki et al.3 observed mutation induction in each of these tissues (6.2, 2.4, and 2.1 fold, respectively). In contrast, they observed no statistically significant mutation induction in nontarget tissues such as the urinary bladder (1.7 x 10-5 versus 1.4 x 10-5 in controls), testis (0.39 x 10-5 versus 0.48 x 10-5 in controls), and bone marrow (1.7 x 10-5 versus 1.3 x 10-5 in controls).

MeIQ

MeIQ (2-amino-3,4-dimethylimidazo[4,5-f ]quinoline) is a potent heterocyclic amine found in the human diet. MeIQ induces tumors in several rat tissues including colon, skin, mammary gland, oral cavity; in the mouse it forms tumors of the forestomach and liver. Several publications have shown that MeIQ induced mutations in Big Blue transgenic rodents.4,5 Induced mutations have been observed in each target tissue except the heart, which is not a target for tumorigenesis. Ushijima et al.5 determined the DNA sequence alterations in mutants recovered from the liver (approximately a 4.5-fold increase in mutant frequency) and bone marrow (approximately a 5-fold increase). A significant tissue-specific difference was seen in the mutant fractions that were GC to TA transversions: 37% in the liver versus only 14% in bone marrow. Consequently, both sequencing DNA and determining mutant frequency are important for more accurately assessing mutation induction and mechanism.

PhIP

PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is a colon carcinogen in the male rat but does not cause tumors in the liver. It induced a 20-fold increase in colon mutations after 400 ppm PhIP was added to the diet.6 We recently determined that no mutations above background are induced in the liver of these animals (de Boer, et al., unpublished). DNA adducts are found in the colon but not the liver. PhIP is metabolically activated in the liver by cytochrome P450, but additional metabolic processing takes place in colon cells.

Ethyleneoxide and Benzene

Sisk et al.7 studied mutation induction in lacI transgenic mice after the mice inhaled 200 ppm of ethylene oxide. The mutant frequency increased significantly in the lung (9.1 x 10-5 versus 6.2 x 10-5 in the controls) but not the spleen, bone marrow, and male germ cells. The lung is indeed a major target organ for tumor formation in the mouse. In another mouse inhalation study with benzene,8 which induces lung tumors, leukemia, and lymphomas, mutations significantly increased in the lung and spleen (a 1.7- and 1.5-fold increase, respectively) but not in the liver tissue. Benzene metabolism takes place partially in the liver, while final oxidation steps can take place in the bone marrow.

Conclusions

The Big Blue transgenic rodent assay system accurately predicts mutations in specific tissues. In a number of cases, mutations are recovered in tissues that are not targets for carcinogenesis. While this eases the screening for mutagenic compounds, it becomes more difficult to determine mutagenic mechanisms and how they relate to carcinogenesis.9 For example, we recently determined that mutation induction in the kidney after TDBP treatment is highest in the cortex layer and less in the outer and inner medulla (de Boer, et al., in preparation). Tumors, however, do not arise in the cortex but in the outer medulla layer. This and other findings indicate that cell proliferation is equally important for tissue-specific tumor formation.

REFERENCES
  1. De Boer, J.G., et al.(1996) Environ. Mol. Mutagen. 28: 418-423.

  2. Mirsalis, J.C., et al.(1993) Mutagenesis 8: 265-271.

  3. Suzuki, T., et al. (1996) Environ. Mol. Mutagen. 28: 348-353.

  4. Suzuki, T., et al. (1996) Mutat. Res. 369: 45-49.

  5. Ushijima, T., et al. (1994) Carcinogenesis 15: 2805-2809.

  6. Okonogi, H., et al. (1997) Mutat. Res. 395: 93-99.

  7. Sisk, S.C., et al. (1997) Mutat. Res. 391: 153-164.

  8. Mullin, A.H., et al. (1995) Mutat. Res. 327: 121-129.

  9. Gorelick, N.J., (1996) Prog. Clin. Biol. Res. 395: 81-108.

  10. Ushijima, T., et al. (1994) Carcinogenesis 15: 2805-2809.

* U.S. Patent No. 5,347,075 and 5,589,155; European Patent No. 0289121;
Japanese Patent No. 2618973.
** U.S. Patent No. 5,188,957.


'"/>

Source:


Page: All 1 2 3 4 5 6 7

Related biology technology :

1. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
2. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
3. Simple Isolation of RNA from Tissue and Cultured Cells
4. Hands-free Tissue Disruption No Homogenization Needed
5. Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue
6. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
7. Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation
8. Genomic DNA Preparation from RNAlater Preserved Tissues
9. DNA Isolation From 300 to 450 mg Dried or 600 to 1,200 mg Fresh Leaf Tissue
10. DNA Isolation From 50 to 20 mg of Paraffin-Embedded Tissue
11. Genomic DNA Isolation From 510 mg Marine Invertebrate Tissue
Post Your Comments:
(Date:9/30/2014)... 30, 2014 CORD:USE Cord Blood Bank – ... it has entered into an Equity and Exclusive Services ... licensed a series of patented technologies for the isolation of ... applications.  Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... solutions for drug discovery and related life ... consortium has chosen Genedata Selector as its ... (NGS) data. FUNGITECT is a European consortium ... fungal diseases via individualized anti-fungal drug therapies. ...
(Date:9/30/2014)... , Sept. 30, 2014  KemPharm, Inc., ... discovery and development of proprietary new molecular entity ... Patent and Trademark Office (USPTO) issued U.S. Patent ... entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl ... Making and Use Thereof." The patent, ...
(Date:9/30/2014)... , Sept. 30, 2014 FemCap Inc., ... health announces its receipt of a patent No: US, ... cup has also received FDA clearance in the U.S., ... the CE in Europe. This patent is related to its ... this issuance, the company is releasing FemmyCycle Teen, a ...
Breaking Biology Technology:CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2
... 16, Shire plc (LSE: SHP, NASDAQ: SHPGY ... U.S. District Court of the Southern District of,New York ... Shire,s patents: U.S. Patent No. 5,968,976 (",976 Patent"); U.S. ... , The lawsuit was filed ...
... and megabase capacity for the next generation sequencing ... febit today announced the official launch ... several biomedical studies of early access customers over ... and deep sequencing coverage for a broad range ...
... tester machine for medical pouches & sachets from Ireland-based manufacturer Sepha. ... ... A leak tester machine for pharmaceutical and medical pouches ... makes its U.S. market debut through U.S. distributor Service Industries ...
Cached Biology Technology:Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents 2Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 2Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 3U.S. Distributor Debut for PAKSCAN - a Pouch & Sachet Leak Tester Machine from Ireland-based Sepha Ltd. 2U.S. Distributor Debut for PAKSCAN - a Pouch & Sachet Leak Tester Machine from Ireland-based Sepha Ltd. 3
(Date:9/30/2014)... tetrachloroethylene (PCE) in drinking water may increase the ... a new study led by a Boston University ... published in the journal Environmental Health , ... among 1,766 women in Cape Cod, Ma., where ... the early 1980s by the installation of vinyl-lined ...
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... in urban and farm runoff in Hawaii is causing ... , The study, published Tuesday in the peer-reviewed ... the runoff ends up in algae that the turtles ... eyes, flippers and internal organs. , Scientists at Duke ... and Atmospheric Administration (NOAA) conducted the study to better ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... University] The cactus, stalwart of the desert, has quite ... found the world over. In a paper published in ... Academy of Sciences , Brown University biologists and colleagues have ... and 10 million years ago and coincided with species explosions ...
... asses are descendants of the original ancestors of the horse ... now in danger of extinction, largely as a direct result ... Walzer,s group has been working together with colleagues in Germany, ... currently restricted to areas in Mongolia, China, India, Iran and ...
... ... cattle in native pasturelands in Brazil,s Pantanal and Cerrado regions can benefit ... Conservation Society. , The technique, which has been adapted ... small areas for shorter periods of time before moving onto other pastures. ...
Cached Biology News:Succulent plants waited for cool, dry Earth to make their mark 2Succulent plants waited for cool, dry Earth to make their mark 3A boring life -- the Asiatic wild ass in the Mongolian Gobi 2Grazing as a conservation tool 2
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
...
...
...
Biology Products: